Onco3R Therapeutics Announces Completion of First Multiple Ascending Dose Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671
Dosing of first MAD cohort in Phase 1 trial of O3R-5671 complete with no drug related adverse events Pharmacokinetic profile demonstrates long half-life and low intersubject variability Pharmacodynamic data from single ascending dose cohorts indicative of profound and sustained TNFα inhibition at low doses Leuven, Belgium. December 3, 2025. Onco3R Therapeutics, a clinical-stage immunology and […]